NERV – minerva neurosciences, inc (US:NASDAQ)
Stock Stats
News
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Minerva Neurosciences (NASDAQ:NERV) had its price target lowered by analysts at HC Wainwright from $5.00 to $4.00. They now have a "neutral" rating on the stock.
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates [Yahoo! Finance]
Form ARS Minerva Neurosciences, For: Dec 31
Form DEF 14A Minerva Neurosciences, For: Dec 22
Form 8-K Minerva Neurosciences, For: Nov 14
Form 4 Minerva Neurosciences, For: Nov 14 Filed by: Kaul Inderjit
Form 3 Minerva Neurosciences, For: Nov 14 Filed by: Kaul Inderjit
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.